Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis

Human Gene Therapy

Volumn 13, Issue 4, 2002, Pages 485-495

  Kruyt, Frank A E ^a   Curiel, David T ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; ONCOLYTIC VIRUS; ONYX 015; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELL DEATH; CELL KILLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADENOVIRUSES, HUMAN; ANTINEOPLASTIC AGENTS; CELL DEATH; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; NEOPLASMS; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA;

EID: 0036210741     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340252809784     Document Type: Review

References (76)

1. Midkine promoter-based adenoviral vector gene therapy for pediatric solid tumors
2. Complementary adenoviral vectors for oncolysis
3. Blood clearance rates of adenovirus type 5 in mice
4. Replicative adenoviruses for cancer therapy
5. Human papillomavirus E6E7-mediated adenovirus cell killing: Selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes
6. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
7. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
8. Induction of cell death by adenoviruses
9. Strategies to adapt adenoviral vectors for targeted delivery
10. The development of conditionally replicative adenoviruses for cancer therapy
11. Efficient induction of cell death by adenoviruses requires binding of E1B55kD and p53
12. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus-independent cell entry mechanism
13. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
14. Targeted gene delivery by tropism-modified adenoviral vectors
15. Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on tumor expression of primary Ad receptors
16. Homologous sequences in adenovirus E1A and human papilloma E7 proteins mediate interaction with the same set of cellular proteins
17. Viral transactivating proteins
18. Mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
19. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
20. Replication and cytolysis of an E1B-attenuated adenovirus in resistant ovarian tumour cells is associated with reduced apoptosis
21. Conditionally replicative adenoviral vectors for cancer gene therapy
22. p53 status does not determine outcome of E1B55-kilodalton mutant adenovirus lytic infection
23. Mitochondria and apoptosis
24. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
25. p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication
26. Wild-type adenovirus decreases tumor xenograft growth but despite viral persistence complete responses are rarely achieved - Deletion of the viral E1b-19-kD gene increases the viral oncolytic effect
27. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region
28. Gen delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7K/gp19K region
29. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and anti-tumoral efficacy that can be augmented by standard chemotherapeutic agents
30. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
31. Efficacy with a replication selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p53 functional status or route of administration
32. Imaging transgene expression in live animals
33. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
34. Clinical research results with dl1520 (ONYX-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?
35. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
36. Advanced generation adenoviral vectors possess augmented transfer efficiency based upon coxsackie adenovirus receptor independent cellular entry capacity
37. The adenovirus type 5 E1B-55K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6, p53 and Mdm2
38. The proto-oncogene Bcl-2 and its role in regulating apoptosis
39. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
40. Immune evasion by adenoviruses
41. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters
42. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression
43. ONYX-015 selectivity and the p14ARF pathway
44. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
45. E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products
46. P53/E1B58kDa complex regulates adenovirus replication
47. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)
48. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
49. 111In]-DTPA-D-Phe-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector
50. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
51. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumour cells
52. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector
53. The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes to the nuclear membrane
54. Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein
55. Studies on the use of viruses in the treatment of carcinoma of the cervix
56. The large E1B protein together with E4ORF6 protein target p53 for active degradation in adenovirus infected cells
57. E1A overcomes the apoptosis block in BCR-ABL + leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents
58. Conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency
59. The 11, 600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection
60. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells
61. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
62. Regulation of apoptosis by adenovirus E1A and E1B oncogenes
63. Targeting adenovirus
64. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies
65. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: Assessment of antitumor efficacy and toxicity
66. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
67. Viruses as antitumor weapons: Defining conditions for remission
68. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
69. Innate immune mechanism dominate elimination of adenoviral vectors following in vivo administration
70. Characterization of the cyclooxygenase -2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers
71. ARF modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53
72. Advances in adenoviral vectors: From genetic engineering to biology
73. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
74. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
75. Simultaneous evaluation of dual gene transfer to adherent cells γ-ray imaging
76. The cytotoxic effect of E1B 55-kDa mutant adenovirus on human hepatocellular carcinoma cell lines